Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-0,21%
1 091,51
-2,30
-0,21%
—1 093,811 096,521 100,221 091,51——
SIXC
Communications
SIXC
Communications
SIXC
+0,22%
610,11
+1,34
+0,22%
—608,77608,77612,97608,77——
SIXE
Energy
SIXE
Energy
SIXE
-1,34%
1 237,98
-16,83
-1,34%
—1 254,811 253,011 253,871 226,33——
SIXI
Industrials
SIXI
Industrials
SIXI
-0,93%
1 744,71
-16,40
-0,93%
—1 761,111 764,271 766,881 744,71——
SIXM
Financials
SIXM
Financials
SIXM
-0,37%
640,18
-2,40
-0,37%
—642,58644,87648,48640,18——
SIXR
Staples
SIXR
Staples
SIXR
-0,18%
849,58
-1,55
-0,18%
—851,13855,66858,75845,56——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-0,23%
217,48
-0,50
-0,23%
—217,98217,98218,65216,88——
SIXT
Technology
SIXT
Technology
SIXT
+1,52%
3 260,69
+48,86
+1,52%
—3 211,833 227,213 268,383 226,55——
SIXU
Utilities
SIXU
Utilities
SIXU
-0,69%
942,45
-6,53
-0,69%
—948,98948,58957,83941,97——
SIXV
Health care
SIXV
Health care
SIXV
-0,52%
1 466,80
-7,72
-0,52%
—1 474,521 479,031 481,041 466,80——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+0,22%
2 397,50
+5,38
+0,22%
—2 392,122 396,952 421,222 382,32——
Q1 2026 earnings • released • EPS beat +6,38% • Revenue beat +3,50%
See results
REGN:NASDAQ
Regeneron Pharmaceuticals Inc
USD 701,42
-0,80%
(-5,64) 1D
USD 702,10
+0,10% (+0,68)
After hours
Closed: 1 Mei, 16:00:00 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for REGN...
Open
USD 703,02
High
USD 714,48
Low
USD 700,26
Mkt. cap
73,54 mjd
Avg. vol.
603,55 k
Volume
729,18 k
Dividend
0,54%
Quarterly dividend
USD 0,94
Ex dividend date
20 Nov. 2025
P/E ratio
17,10
52-wk high
USD 821,11
52-wk low
USD 476,49
EPS
USD 41,03
Beta
0,40
Shares outstanding
103,02 m
No. of employees
15 k
News stories
From sources across the web
Profile
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its present name; the company has since expanded operations into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a VEGF-trap. Wikipedia
About Regeneron Pharmaceuticals Inc
CEOLeonard Schleifer
Employees15,4 k
Founded1988
HeadquartersTarrytown, New York, Verenigde State van Amerika
Sector-
Websiteregeneron.com
Last report
29 Apr. 2026
Fiscal Period
Q1 2026
Normalized EPS / Estimate
9,47/ (8,90 est.)USD
+6,38%beat
Revenue / Estimate
3,61 mjd/ (3,48 mjd est.)USD
+3,50%beat
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glanceInsights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun. 2025
Sep. 2025
Des. 2025
Mrt. 2026
Revenue
3,68 mjd
3,75 mjd
3,88 mjd
3,61 mjd
Cost of goods sold
1,95 mjd
2,00 mjd
2,21 mjd
2,11 mjd
Cost of revenue
1,95 mjd
2,00 mjd
2,21 mjd
2,11 mjd
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
634,20 m
657,80 m
775,00 m
652,70 m
Operating expense
634,20 m
647,80 m
775,00 m
652,70 m
Total operating expenses
2,59 mjd
2,64 mjd
2,99 mjd
2,76 mjd
Operating income
1,09 mjd
1,11 mjd
898,60 m
846,50 m
Other non operating income
18,20 m
3,00 m
958,50 m
176,20 m
EBT including unusual items
1,52 mjd
1,76 mjd
1,04 mjd
831,20 m
EBT excluding unusual items
1,28 mjd
1,27 mjd
2,04 mjd
1,01 mjd
Income tax expense
127,10 m
303,30 m
199,10 m
104,00 m
Effective tax rate
8,37%
17,20%
19,08%
12,51%
Other operating expenses
-
-10,00 m
-
-
Net income
1,39 mjd
1,46 mjd
844,60 m
727,20 m
Net profit margin
37,86%
38,89%
21,74%
20,17%
Earnings per share
12,89
11,83
11,44
9,47
Interest and investment income
174,80 m
175,10 m
193,30 m
-
Interest expense
-3,60 m
-19,30 m
-12,20 m
-12,90 m
Net interest expenses
171,20 m
155,80 m
181,10 m
-12,90 m
Depreciation and amortization charges
-
-
-
-
EBITDA
1,22 mjd
1,25 mjd
1,04 mjd
982,42 m
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer